<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01461005</url>
  </required_header>
  <id_info>
    <org_study_id>Dynamic Stabilization System</org_study_id>
    <nct_id>NCT01461005</nct_id>
  </id_info>
  <brief_title>A Postmarket Surveillance Study of the Paradigm Spine Dynamic Stabilization System (DSS)</brief_title>
  <acronym>DSS</acronym>
  <official_title>A Postmarket Surveillance Study of the Paradigm Spine Dynamic Stabilization System(DSS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Paradigm Spine</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Musculoskeletal Clinical Regulatory Advisers</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Paradigm Spine</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the Post-Market Surveillance study is to evaluate safety.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Paradigm Spine Dynamic Stabilization System (DSS) study is a prospective, multi-center,
      literature controlled study.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    FDA reclassified so all 522 studies were stopped,
  </why_stopped>
  <start_date>September 2011</start_date>
  <completion_date type="Actual">September 2016</completion_date>
  <primary_completion_date type="Actual">September 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants Who Have an Incidence of Serious or Device Related Adverse Events Due to Device or Procedure.</measure>
    <time_frame>6 months</time_frame>
    <description>The safety endpoint is defined as the incidence of serious or device related adverse events attributable to the device or procedure. Reoperations, revisions or removals of the Dynamic Stabilization System (DSS) System implant will be evaluated.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Measurement of Lower Back Pain as Assessed by Visual Analog Scale</measure>
    <time_frame>6 months</time_frame>
    <description>Lower back pain as measured by the Visual Analog Scale (VAS) on the scale from 0 (no pain) to 100 (worst imaginable pain)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measurement of Right Leg Pain as Assessed by Visual Analog Scale</measure>
    <time_frame>6 months</time_frame>
    <description>Right leg pain as measured by the Visual Analog Scale (VAS) on the scale from 0 (no pain) to 100 (worst imaginable pain)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measurement of Left Leg Pain as Assessed by Visual Analog Scale</measure>
    <time_frame>6 months</time_frame>
    <description>Left leg pain as measured by the Visual Analog Scale (VAS) on the scale from 0 (no pain) to 100 (worst imaginable pain)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Improved Health as Measured by the EuroQOL Health Related Qualify of Life- 5 Dimensions-3 Level (EQ-5D-3L) Health Questionnaire Compared to Baseline.</measure>
    <time_frame>Pre-Op, 6 weeks, 6 months, 12 months, and 24 months</time_frame>
    <description>The EQ-5D-3L is a standardized instrument used as a measure of health outcomes. It contains questions in 5 dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) and provides a simple descriptive profile and single index for health status preference. In addition, there is a Visual Analog Scale (VAS). The VAS is the participant's rating of their health on a scale of 0 &quot;worst imaginable health state&quot; to 100 &quot;best imaginable health state&quot;.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of Back Pain Using the Oswestry Low Back Pain Disability Index (ODI).</measure>
    <time_frame>6 months</time_frame>
    <description>ODI is a questionnaire that provides information on back and the affects on managing every day life by diving questions into 10 sections. The total possible score for each section is 0-5. The scores are then converted into percentages ranging from 0% (minimal disability) to 100% (maximum possible disability).</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">1</enrollment>
  <condition>Spondylolisthesis</condition>
  <condition>Neurologic Deficits</condition>
  <condition>Kyphosis</condition>
  <condition>Pseudarthrosis</condition>
  <arm_group>
    <arm_group_label>Dynamic Stabilization System</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dynamic Stabilization System (DSS) System</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Dynamic Stabilization System (DSS)</intervention_name>
    <description>Dynamic Stabilization System</description>
    <arm_group_label>Dynamic Stabilization System</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient is skeletally mature (21-85 years old).

          -  Patient has degenerative spondylolisthesis (Grade 1-3) with objective evidence of
             neurologic impairment, kyphosis, and/or failed previous fusion (pseudarthrosis) at
             index level.

          -  Capable and willing to comply with the requirements unique to the study, adhere to the
             post-operative treatment and management program, and return for required follow-up
             examinations.

          -  Surgeon has determined that DSS™ System is an appropriate treatment for the patient
             without regard to the study.

        Exclusion Criteria:

          -  The need for interbody cages, allograft, or any other assistance during surgery.
             Device is only to be used with autograft per FDA approved indications.

          -  Any medical, mental or surgical condition precluding the potential benefit of spinal
             surgery or surgery in general.

          -  Acute or chronic systemic, spinal or localized infections.

          -  Active, severe systemic and metabolic diseases.

          -  Obesity defined as Body Mass Index &gt; 35.

          -  Subject is pregnant or interested in becoming pregnant in the next 36 months.

          -  Dependency on pharmaceutical drugs, drug abuse, or alcoholism.

          -  Lack of patient cooperation.

          -  Foreign body sensitivity to the implant material.

          -  Degenerative scoliosis greater than 25 degrees.

          -  Grade 4 degenerative spondylolisthesis (&gt;75% slip).

          -  Significant osteopenia A screening questionnaire for osteopenia, SCORE (Simple
             Calculated Osteoporosis Risk Estimation), will be used to screen patients who require
             a DEXA bone mineral density measurement. If DEXA is required*, exclusion will be
             defined as a DEXA bone density measured T score of ≤ -1.0 (The World Health
             Organization definition of osteopenia).

          -  Soft tissue deficit not allowing wound closure.

          -  Congenital abnormalities, tumors or other conditions that would prevent secure
             component fixation that has the potential to decrease the useful life of the device.

          -  Inadequate pedicles or vertebral body geometry of the thoracic, lumbar and sacral
             vertebrae.

          -  Bony lumbar spinal stenosis not related to the primary degenerative spondylolisthesis
             indication.

          -  Pars defect.

          -  Clinically compromised vertebral bodies at affected level due to current or past
             trauma.

          -  Prisoner or ward of the state.

          -  Currently in litigation regarding a spinal condition.

          -  Known allergy to titanium, titanium alloys, CoCrMo, polyethylene or MR contrast
             agents.

          -  Is currently involved in a study of another investigational product for similar
             purpose.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gitela Gandelman</last_name>
    <role>Study Director</role>
    <affiliation>Paradigm Spine LLC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California, Davis Medical Center</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95816</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>October 18, 2011</study_first_submitted>
  <study_first_submitted_qc>October 26, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 27, 2011</study_first_posted>
  <results_first_submitted>January 11, 2019</results_first_submitted>
  <results_first_submitted_qc>October 12, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">October 15, 2019</results_first_posted>
  <last_update_submitted>February 6, 2020</last_update_submitted>
  <last_update_submitted_qc>February 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Spondylolisthesis</keyword>
  <keyword>Neurologic impairment</keyword>
  <keyword>Kyphosis</keyword>
  <keyword>Pseudarthrosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Spondylolisthesis</mesh_term>
    <mesh_term>Kyphosis</mesh_term>
    <mesh_term>Neurologic Manifestations</mesh_term>
    <mesh_term>Pseudarthrosis</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Dynamic Stabilization System</title>
          <description>Dynamic Stabilization System (DSS) System
Dynamic Stabilization System (DSS): Dynamic Stabilization System</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>FDA reclassified Dynamic Stabilization D</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>DSS Stabilization System</title>
          <description>DSS Stabilization System</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="67" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Who Have an Incidence of Serious or Device Related Adverse Events Due to Device or Procedure.</title>
        <description>The safety endpoint is defined as the incidence of serious or device related adverse events attributable to the device or procedure. Reoperations, revisions or removals of the Dynamic Stabilization System (DSS) System implant will be evaluated.</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Dynamic Stabilization System</title>
            <description>Dynamic Stabilization System (DSS) System
Dynamic Stabilization System (DSS): Dynamic Stabilization System</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Have an Incidence of Serious or Device Related Adverse Events Due to Device or Procedure.</title>
          <description>The safety endpoint is defined as the incidence of serious or device related adverse events attributable to the device or procedure. Reoperations, revisions or removals of the Dynamic Stabilization System (DSS) System implant will be evaluated.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Measurement of Lower Back Pain as Assessed by Visual Analog Scale</title>
        <description>Lower back pain as measured by the Visual Analog Scale (VAS) on the scale from 0 (no pain) to 100 (worst imaginable pain)</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Dynamic Stabilization System</title>
            <description>Dynamic Stabilization System (DSS) System
Dynamic Stabilization System (DSS): Dynamic Stabilization System</description>
          </group>
        </group_list>
        <measure>
          <title>Measurement of Lower Back Pain as Assessed by Visual Analog Scale</title>
          <description>Lower back pain as measured by the Visual Analog Scale (VAS) on the scale from 0 (no pain) to 100 (worst imaginable pain)</description>
          <units>units on a scale</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Measurement of Right Leg Pain as Assessed by Visual Analog Scale</title>
        <description>Right leg pain as measured by the Visual Analog Scale (VAS) on the scale from 0 (no pain) to 100 (worst imaginable pain)</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>DSS Stabilization System</title>
            <description>DSS Stabilization System</description>
          </group>
        </group_list>
        <measure>
          <title>Measurement of Right Leg Pain as Assessed by Visual Analog Scale</title>
          <description>Right leg pain as measured by the Visual Analog Scale (VAS) on the scale from 0 (no pain) to 100 (worst imaginable pain)</description>
          <units>units on a scale</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Measurement of Left Leg Pain as Assessed by Visual Analog Scale</title>
        <description>Left leg pain as measured by the Visual Analog Scale (VAS) on the scale from 0 (no pain) to 100 (worst imaginable pain)</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>DSS Stabilization System</title>
            <description>DSS Stabilization System</description>
          </group>
        </group_list>
        <measure>
          <title>Measurement of Left Leg Pain as Assessed by Visual Analog Scale</title>
          <description>Left leg pain as measured by the Visual Analog Scale (VAS) on the scale from 0 (no pain) to 100 (worst imaginable pain)</description>
          <units>units on a scale</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Improved Health as Measured by the EuroQOL Health Related Qualify of Life- 5 Dimensions-3 Level (EQ-5D-3L) Health Questionnaire Compared to Baseline.</title>
        <description>The EQ-5D-3L is a standardized instrument used as a measure of health outcomes. It contains questions in 5 dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) and provides a simple descriptive profile and single index for health status preference. In addition, there is a Visual Analog Scale (VAS). The VAS is the participant's rating of their health on a scale of 0 &quot;worst imaginable health state&quot; to 100 &quot;best imaginable health state&quot;.</description>
        <time_frame>Pre-Op, 6 weeks, 6 months, 12 months, and 24 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>DSS Stabilization System</title>
            <description>DSS Stabilization System</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Improved Health as Measured by the EuroQOL Health Related Qualify of Life- 5 Dimensions-3 Level (EQ-5D-3L) Health Questionnaire Compared to Baseline.</title>
          <description>The EQ-5D-3L is a standardized instrument used as a measure of health outcomes. It contains questions in 5 dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) and provides a simple descriptive profile and single index for health status preference. In addition, there is a Visual Analog Scale (VAS). The VAS is the participant's rating of their health on a scale of 0 &quot;worst imaginable health state&quot; to 100 &quot;best imaginable health state&quot;.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Assessment of Back Pain Using the Oswestry Low Back Pain Disability Index (ODI).</title>
        <description>ODI is a questionnaire that provides information on back and the affects on managing every day life by diving questions into 10 sections. The total possible score for each section is 0-5. The scores are then converted into percentages ranging from 0% (minimal disability) to 100% (maximum possible disability).</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>DSS Stabilization System</title>
            <description>DSS Stabilization System</description>
          </group>
        </group_list>
        <measure>
          <title>Assessment of Back Pain Using the Oswestry Low Back Pain Disability Index (ODI).</title>
          <description>ODI is a questionnaire that provides information on back and the affects on managing every day life by diving questions into 10 sections. The total possible score for each section is 0-5. The scores are then converted into percentages ranging from 0% (minimal disability) to 100% (maximum possible disability).</description>
          <units>score on a scale</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>6 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Dynamic Stabilization System</title>
          <description>Dynamic Stabilization System (DSS) System
Dynamic Stabilization System (DSS): Dynamic Stabilization System</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Justin Eggleton, Senior Director, Spine Regulatory Affairs</name_or_title>
      <organization>MCRA</organization>
      <phone>2025525804</phone>
      <email>jeggleston@mcra.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

